EMMPRIN is an emerging protein capable of regulating cancer hallmarks.
Brenda de la Cruz-Concepción, L D Bartolo-García, M D Tizapa-Méndez, M Martínez-Vélez, J J Valerio-Diego, Berenice Illades‐Aguiar, Eric Genaro Salmerón-Bárcenas, J Ortiz-Ortiz, Francisco Israel Torres‐Rojas, M Á Mendoza-Catalán, Napoleón Navarro‐Tito, A E Zacapala-Gómez
Abstract
EMMPRIN, also known as Basigin or CD147, is a transmembrane glycoprotein member of the immunoglobulin superfamily. It is expressed basally in cells that regulate physiological processes of the cardiovascular, nervous, and immune systems. However, EMMPRIN is also capable of interacting with different proteins, like VEGFR, SMAD4, Integrin, MCT, CyPA, GLUT1, CAIV, Annexin II, Cav-1, CAML, etc., and regulating signaling pathways that stimulate the cell processes of proliferation, apoptosis, metabolism, adhesion, invasion, migration, metastasis, tumor immune response, and angiogenesis processes, which favors the development of different types of cancer. EMMPRIN is the first protein reported that favors cancer development due to its ability to interact with extracellular, intracellular, and membrane proteins. In conclusion, EMMPRIN regulates several proteins associated with the development of tumor processes. Therefore, blocking the expression of EMMPRIN can be a therapeutic target, and the analysis of its expression can be used as an important biomarker in cancer.